SEC Form D filing

KALA BIO, Inc., 2026-03-17

An SEC Form D private-offering notice from Arlington, MA, a $1,753,500 filer-stated offering target in Biotech. Filed 2026-03-17. The source filing is one click away. For companies that filed this week, open the live feed.

What this filing says

KALA BIO, Inc. site↗ Verified via SEC Form D

Clinical stage biopharmaceutical company developing therapies for rare and severe eye diseases, formerly Kala Pharmaceuticals, publicly traded on Nasdaq as KALA.

Filed 2026-03-17Filed to raise $1,753,500First money in 2026-03-03Raised so far $1,753,500HQ (as filed) Arlington, MASector Biotech web-verified against the company’s own siteStage (inferred) Seed
Source linked the Form D on EDGAR↗Website verified kalarx.com↗Named in the filing 5 executives & directors
Open this row on the live feed →More new filings in Massachusetts →More Biotech filings →

This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.

Other Form D filings from the same week

each with its own page and its own EDGAR source